However, the antitumor activity of MEK1/2 inhibitors in monotherapy or in combination with conventional chemotherapy has been demonstrated to be ineffective in a significant proportion of patients with KRAS-mutant advanced NSCLC [9, 10]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.